Chimeric: Media Thread, page-609

why wouldn't they as long as safety checks out.

I think you guys are looking way too much into the percentages of a very small trial. 11 people and only 6 showed disease control. That will skew the percentages. Wait for 50-60 patient trial

Rose colored glasses aside, the market didn't re-rate on the back of the 1a data, likely because it's way too small and didn't show anything conclusive. More of the same old same old as all other trials. 3 years down and many more years to go.

IPO at 20c, now at 2.5c. Management pay themselves as if they are running a fortune 500 company. That is never a good sign. Taking as much as they can before this goes to zero